---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-056122"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:11:00.886542+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dyne reports Q3 net loss $60.2M, cash $157.8M; clinical data due Jan 2024

## Summary
- Cash, cash equivalents and marketable securities of $157.8M; funding expected through 2024.
- Net loss of $60.2M ($0.99 per share) vs. $41.4M ($0.80) in Q3 2022; R&D expenses rose to $55.3M from $34.7M.
- ACHIEVE trial (DYNE-101 in DM1) fully enrolled through 3.4 mg/kg; dose escalation to 6.8 mg/kg enrolling; over 150 doses, no anemia or discontinuations.
- DELIVER trial (DYNE-251 in DMD) fully enrolled through 10 mg/kg; dose escalation to 20 mg/kg enrolling; over 175 doses, no anemia or discontinuations.
- Initial safety, splicing, dystrophin and functional data from both trials expected around J.P. Morgan Healthcare Conference in early January 2024.

## SEC filing metadata
- accession: 0000950170-23-056122
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017023056122/0000950170-23-056122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017023056122/dyn-20231030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-056122
- JSON: https://secwatch.observer/filing/0000950170-23-056122.json
- Plain text: https://secwatch.observer/filing/0000950170-23-056122.txt

## Key facts
- Earnings Releases
  Dyne Therapeutics, Inc. reported September 30, 2023 results: net income Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share., EPS $0.99.
  - Period: September 30, 2023
  - Net income: Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.
  - EPS: $0.99
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023 was $60.2 million, or $0.99 per basic and diluted share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818794/000095017023056122/0000950170-23-056122-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.